Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H9Cl3N2O |
Molecular Weight | 315.582 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(NC(=O)NC2=CC=C(Cl)C(Cl)=C2)C=C1
InChI
InChIKey=ICUTUKXCWQYESQ-UHFFFAOYSA-N
InChI=1S/C13H9Cl3N2O/c14-8-1-3-9(4-2-8)17-13(19)18-10-5-6-11(15)12(16)7-10/h1-7H,(H2,17,18,19)
Molecular Formula | C13H9Cl3N2O |
Molecular Weight | 315.582 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created using several sources including:
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm517478.htm; http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/economicanalyses/ucm519798.pdf; https://www.ncbi.nlm.nih.gov/pubmed/22626523; https://www.ncbi.nlm.nih.gov/pubmed/21131331; http://www.ncbi.nlm.nih.gov/pubmed/?term=12534815
Curator's Comment: Description was created using several sources including:
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm517478.htm; http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/economicanalyses/ucm519798.pdf; https://www.ncbi.nlm.nih.gov/pubmed/22626523; https://www.ncbi.nlm.nih.gov/pubmed/21131331; http://www.ncbi.nlm.nih.gov/pubmed/?term=12534815
Triclocarban is a triclosan analogue with an antibmicrobial property. It has been used in a wide range of personal cleansing products including deodorant and bar soaps, deodorants, detergents, cleansing lotions, and wipes. In US triclocarban was approved for marketing of over-the-counter (OTC) consumer antiseptic wash products. But on September 2, 2016 U.S. Food and Drug Administration banned containing triclocarban and triclosan consumer antiseptic wash products from further marketing in USA because of a potential damage to human health, resulting from extended exposure to antiseptic active ingredients on a regular bases. However the new rule does not not affect consumer hand “sanitizers” or wipes, or antibacterial products used in health care settings. Triclocarban is a limited spectrum antibacterial agent effective in vitro against some strains of staphylococcus, streptococcus, and enterococcus bacteria. The minimum inhibitory concentration has been found to range from 0.5 to 8 mg/L for these various strains. Triclocarban can act by non-specific membrane-destabilizing mechanism; also was suggested, that similar to triclosan, Triclocarban exerts its effect by inhibiting the activity of enoyl-(acyl-carrier protein) (ACP) reductase, widely distributed in bacteria, fungi and plants. As a result, this agent interrupts cell membrane synthesis and leads to bacterial growth inhibition.
Approval Year
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1109279/ |
103 μg single, intravenous dose: 103 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
TRICLOCARBAN blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
9 % 1 times / day multiple, topical Highest studied dose Dose: 9 %, 1 times / day Route: topical Route: multiple Dose: 9 %, 1 times / day Sources: |
healthy, 21 to 65 years old n = 10 Health Status: healthy Age Group: 21 to 65 years old Sex: M Population Size: 10 Sources: |
Other AEs: Skin irritation... Other AEs: Skin irritation (grade 1) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Skin irritation | grade 1 | 9 % 1 times / day multiple, topical Highest studied dose Dose: 9 %, 1 times / day Route: topical Route: multiple Dose: 9 %, 1 times / day Sources: |
healthy, 21 to 65 years old n = 10 Health Status: healthy Age Group: 21 to 65 years old Sex: M Population Size: 10 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Activity and mechanisms of action of selected biocidal agents on Gram-positive and -negative bacteria. | 2003 |
|
Simultaneous determination of chlorinated bacteriostats in cosmetic and pharmaceutical products. | 2005 May-Jun |
|
Detection of triclocarban and two co-contaminating chlorocarbanilides in US aquatic environments using isotope dilution liquid chromatography tandem mass spectrometry. | 2007 Jan |
|
Snail bioaccumulation of triclocarban, triclosan, and methyltriclosan in a North Texas, USA, stream affected by wastewater treatment plant runoff. | 2008 Aug |
|
Growth-inhibiting effects of 12 antibacterial agents and their mixtures on the freshwater microalga Pseudokirchneriella subcapitata. | 2008 May |
|
Determination of household chemicals using gas chromatography and liquid chromatography with tandem mass spectrometry. | 2008 May 9 |
|
Runoff of pharmaceuticals and personal care products following application of dewatered municipal biosolids to an agricultural field. | 2009 Aug 1 |
|
Fate of organohalogens in US wastewater treatment plants and estimated chemical releases to soils nationwide from biosolids recycling. | 2009 Dec |
|
Adsorption and degradation of triclosan and triclocarban in soils and biosolids-amended soils. | 2009 Jun 10 |
|
Effect of triclosan and triclocarban biocides on biodegradation of estrogens in soils. | 2009 Nov |
|
On-line solid-phase extraction of large-volume injections coupled to liquid chromatography-tandem mass spectrometry for the quantitation and confirmation of 14 selected trace organic contaminants in drinking and surface water. | 2009 Nov 27 |
|
Occurrence and risks of triclosan and triclocarban in the Pearl River system, South China: from source to the receiving environment. | 2010 Jul 15 |
|
Self-reported chemicals exposure, beliefs about disease causation, and risk of breast cancer in the Cape Cod Breast Cancer and Environment Study: a case-control study. | 2010 Jul 20 |
|
Analysis of triclosan and triclocarban in soil and biosolids using molecularly imprinted solid phase extraction coupled with HPLC-UV. | 2010 Jul-Aug |
|
Quantitative gene monitoring of microbial tetracycline resistance using magnetic luminescent nanoparticles. | 2010 Jun |
|
Quantitative determination of triclocarban in wastewater effluent by stir bar sorptive extraction and liquid desorption-liquid chromatography-tandem mass spectrometry. | 2010 Mar 12 |
|
Aquatic hazard assessment for pharmaceuticals, personal care products, and endocrine-disrupting compounds from biosolids-amended land. | 2010 Oct |
|
Triclocarban and triclosan biodegradation at field concentrations and the resulting leaching potentials in three agricultural soils. | 2010 Sep |
|
Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells. | 2013 Aug |
Patents
Sample Use Guides
Use Dial® soap containing 0.30% triclocarban for hand and body wash
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=12534815
To study effects of antimicrobial agents on the growth of P. aeruginosa at 37°C triclocarban at concentrations of 0 - 5 ug/ml were used
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:17 GMT 2023
by
admin
on
Fri Dec 15 15:22:17 GMT 2023
|
Record UNII |
BGG1Y1ED0Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
27901
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3630
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
m11089
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
2017
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
C47770
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
202-924-1
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
38609
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
BGG1Y1ED0Y
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
7547
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
TRICLOCARBAN
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
72005
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
5009
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
1681800
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
48347
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
C009540
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
BGG1Y1ED0Y
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
DB11155
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
100000077518
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1076347
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
101-20-2
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
SUB11271MIG
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
DTXSID4026214
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||